Biocon

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE376G01013
  • NSEID: BIOCON
  • BSEID: 532523
INR
426.10
-0.25 (-0.06%)
BSENSE

Aug 10, 03:30 PM

BSE+NSE Vol: 24.21 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Laurus Labs
Lupin
Ipca Labs
Mankind Pharma
Biocon
Glenmark Pharma
Anthem Bioscienc
Aurobindo Pharma
Alkem Lab
Abbott India
Dr Reddy's Labs

Why is Biocon Ltd. ?

1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.47 times
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.47 times
  • The company has been able to generate a Return on Equity (avg) of 4.95% signifying low profitability per unit of shareholders funds
2
Flat results in Jun 26
  • PBT LESS OI(Q) At Rs 86.60 cr has Fallen at -31.9% (vs previous 4Q average)
  • ROCE(HY) Lowest at 3.72%
  • PAT(Q) At Rs 154.60 cr has Fallen at -19.5% (vs previous 4Q average)
3
With ROCE of 3.3, it has a Attractive valuation with a 1.8 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 25.24%, its profits have risen by 140% ; the PEG ratio of the company is 0.8
4
High Institutional Holdings at 31.53%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating performance in long term as well as near term
  • Along with generating 25.24% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Biocon should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Biocon for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Biocon
24.1%
0.94
25.63%
Sensex
-1.65%
-0.12
13.58%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
19.16%
EBIT Growth (5y)
11.24%
EBIT to Interest (avg)
4.69
Debt to EBITDA (avg)
4.70
Net Debt to Equity (avg)
0.34
Sales to Capital Employed (avg)
0.43
Tax Ratio
13.00%
Dividend Payout Ratio
5.92%
Pledged Shares
0
Institutional Holding
31.53%
ROCE (avg)
5.99%
ROE (avg)
4.95%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
80
Industry P/E
37
Price to Book Value
2.06
EV to EBIT
54.88
EV to EBITDA
23.08
EV to Capital Employed
1.79
EV to Sales
4.71
PEG Ratio
0.83
Dividend Yield
0.12%
ROCE (Latest)
3.29%
ROE (Latest)
2.26%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company
PAT(9M)

Higher at Rs 782.21 Cr

DEBT-EQUITY RATIO(HY)

Lowest at 0.45 times

-9What is not working for the Company
PBT LESS OI(Q)

At Rs 86.60 cr has Fallen at -31.9% (vs previous 4Q average

ROCE(HY)

Lowest at 3.72%

PAT(Q)

At Rs 154.60 cr has Fallen at -19.5% (vs previous 4Q average

NON-OPERATING INCOME(Q)

is 38.63 % of Profit Before Tax (PBT

Loading Valuation Snapshot...

Here's what is working for Biocon

Debt-Equity Ratio - Half Yearly
Lowest at 0.45 times
in the last five half yearly periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Biocon

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 86.60 cr has Fallen at -31.9% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 127.08 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 154.60 cr has Fallen at -19.5% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 192.14 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Non Operating Income - Quarterly
is 38.63 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT